Filing identity and reporting period
Important identity mismatch: The supplied filing is FS Development Corp.’s Form 10-Q, not a filing identified as Disc Medicine, Inc. It reports the period ended September 30, 2020; FS Development was incorporated June 25, 2020, so the financial statements cover its inception and initial public-company period rather than a comparable prior-year quarter. FS Development was a blank-check company seeking a business combination.
Financial condition and results
| Metric | Amount / detail |
|---|---|
| Revenue | No operating revenue; the company had not commenced operations. Revenue was not expected before a business combination. |
| Net loss | $499,411 for the three months ended September 30, 2020; $500,911 from inception through September 30, 2020. |
| Expenses and income | Quarterly general and administrative expense of $450,986 and franchise tax expense of $49,914, partly offset by $1,489 of trust-account interest income. |
| Cash and liquidity | At September 30, cash outside the trust was $1,437,928; working capital was approximately $1.1 million; trust-account cash equivalents were approximately $120.8 million. |
| Cash flows | From inception: operating cash used, $190,568; investing cash used, $120.75 million; financing cash provided, $122.38 million; ending cash, $1,437,928. |
| Debt and liabilities | No long-term debt reported. The $200,000 sponsor note was repaid August 14, 2020; no working-capital loans were outstanding. Total liabilities were $4,778,652, including $4,226,250 of deferred underwriting commissions payable only if a business combination closes. |
Profit margins are not meaningful for this pre-combination shell company with no operating revenue. The balance sheet also classified $112,580,330 of redeemable Class A shares as temporary equity, separate from stockholders’ equity.
Changes and material developments
- The company completed its IPO on August 14, 2020, selling 12,075,000 public shares at $10 per share for approximately $120.8 million gross proceeds. It also raised approximately $4.4 million in a sponsor private placement. Approximately $120.8 million was placed in trust.
- On October 15, 2020, after the reporting date, FS Development entered into a merger agreement to acquire Gemini Therapeutics, Inc. Gemini would become a wholly owned subsidiary, and FS Development would be renamed Gemini Therapeutics, Inc. This was a proposed transaction, not a completed combination as of the filing.
- The merger consideration could include up to 21.5 million Class A shares, subject to adjustments; 2.15 million shares were to be placed in escrow for indemnification. Investors agreed to subscribe for 9,506,000 shares at $10 each, or $95.06 million gross. Certain public stockholders agreed not to redeem 2,742,529 shares.
- There is no meaningful prior-year comparison because the company was formed in June 2020.
Outlook, risks, and unusual items
- Management said available working capital and potential sponsor or insider borrowing capacity were expected to fund needs through the earlier of a business combination or one year from the filing. Such additional loans were not committed.
- The merger was subject to customary approvals and other closing conditions, including at least $170 million of aggregate cash from the trust and subscriptions after redemptions and unpaid liabilities, and Nasdaq listing approval. The agreement could be terminated under specified circumstances, including failure to close by April 15, 2021, subject to a possible extension.
- If no business combination is completed by August 14, 2022, the company must cease operations and redeem public shares under the terms described in the filing.
- Management stated that the COVID-19 pandemic’s specific impact was not readily determinable; the financial statements included no related adjustments. Management reported no material changes to previously disclosed risk factors.
- The company paid its sponsor $10,000 per month for administrative services and recognized $20,000 of expense through September 30. The sponsor’s earlier indication of interest in a $25 million private placement was nonbinding; the later disclosed subscription agreements totaled $95.06 million, including the sponsor.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. No legal proceedings or off-balance-sheet arrangements were reported.
Key facts for investors to verify
- Confirm the filing belongs to FS Development Corp., not Disc Medicine, Inc., and identify the intended issuer and reporting period.
- Check the subsequent merger agreement and later filings for transaction completion, final share consideration, financing, redemptions, and satisfaction of the $170 million cash condition.
- Verify trust-account balances, redemption rights and limits, deferred underwriting commissions, and the liquidation deadline.
- Review later disclosures for changes in liquidity, sponsor financing, COVID-19 effects, and the combined company’s financial results and outlook.